WHO Advises Against Weight Loss Drugs for Children, Citing Insufficient Data
Translated & summarized from Vesty by baba
The World Health Organization (WHO) recommends lifestyle changes over weight loss drugs for children and adolescents with obesity, citing insufficient data on safety and long-term effectiveness. While some GLP-1 medications are approved for older children and teens in the US and EU, the WHO advises caution, especially for those under 10. In Israel, Wegovy is approved for adolescents over 12 and included in the national health basket for ages 12-18 with professional support. Experts emphasize that medication should supplement, not replace, comprehensive lifestyle interventions.
The story in 6 lines · by baba
- WHO recommends lifestyle changes over weight loss drugs for childhood obesity, citing insufficient data.
- GLP-1 drugs are being prescribed to children as young as 8 in the US, contrary to WHO advice.
- WHO guidelines differentiate treatment for children under 10 and adolescents aged 10-19.
- In Israel, Wegovy is approved for adolescents over 12 and included in the national health basket for ages 12-18.
- Experts highlight concerns about real-world drug effectiveness, weight regain, and muscle mass loss in children.
- WHO stresses the need for a holistic approach including mental health, family support, and societal changes.
The World Health Organization (WHO) has issued new guidelines recommending lifestyle changes over medication for childhood obesity, despite a fourfold increase in the condition over the past 25 years. The recommendations come amid a surge in demand for GLP-1 drugs, commonly used for adult obesity, which are now being prescribed to children as young as 8 in the United States. The WHO's first-ever guidelines on the topic, released on October 7, emphasize balanced nutrition, physical activity, and behavioral therapy, advising against injections and surgeries for children under 10 due to safety and efficacy concerns.
For adolescents aged 10-19, the WHO permits approved medications only if lifestyle interventions fail. Bariatric surgery is considered for severe cases under strict conditions, but the organization notes insufficient research on its long-term benefits and risks in this age group. Similarly, the WHO finds data on GLP-1 drugs for children inadequate, though it acknowledges ongoing research and potential future revisions to its stance. Despite this, some GLP-1 medications are already approved for adolescents in the US and EU, and clinical trials are underway for younger children.
In the US, prescriptions for these drugs among children aged 8-11 with obesity have dramatically increased since 2019, though still used by a small percentage. American guidelines permit treatment from age 8, contrasting with the WHO's cautious approach. The WHO stresses that obesity treatment must focus on overall health and well-being, addressing mental health issues and social factors like stigma and bullying, with family involvement being crucial.
Professor Dani Nemet from Meir Medical Center in Kfar Saba, Israel, supports the WHO's emphasis on lifestyle changes, noting that while drugs show promise in trials, real-world effectiveness is lower and often leads to weight regain, with potential loss of muscle mass. He also points out that subsidized medications are more accessible than comprehensive programs, highlighting the need for systemic healthcare policies. In Israel, Wegovy is approved for adolescents over 12 with high BMI and weight, and was included in the national health basket for ages 12-18 in early 2026, contingent on professional support programs.
Mentioned
Not the same event — other stories that share this one’s people, places, or theme: background, reactions, and follow-ups.
